COVID-19 (Coronavirus) Update

As the level of COVID-19 infections begins to stabilize in our community, we are starting to reschedule appointments, surgeries, and procedures that were delayed during the pandemic. Learn more about how Duke Health is committed to keeping you safe. Visitor restrictions remain in effect. 

ImmunoGen:0801 Phase1 IMGN632 in R/R CD123+AML/other CD123+HM (Leukemia) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out what dose of the study drug IMGN632 is a good idea for patients who have cancer and to learn what effects, good and/or bad, the study drug may have on patients.
What is the Condition Being Studied?
CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies

Who Can Participate in the Study?

Adult men and women who have:
- First relapse of CD123+ AML
- Relapse of CD123+ ALL
- Relapse of CD123+ "other" hematologic malignancies
- Relapse of CD123+ BPDCN

Age Group

What is Involved?

If you choose to join this study, you will:

- Go through a screening process that includes:
-- Review of medical history
-- Having a bone marrow aspirate (removal of soft tissue in the bone) that must be done at Duke
-- Blood tests
-- Physical exams
-- PET/CT Scans (if needed)
-- ECHO/MUGA scan
-- Cheek swab (if enrolled on dose expansion)
-- other tests

- Be in one of the following groups:
-- The first phase of the study which will find out the highest and safe dose of the study drug IMGN632 through infusion at Duke clinic
-- You will get one of multiple expansion phases

- Have a complete physical exam, vital signs, and performance status
- Have symptom-directed physical exam
- Have blood tests for safety and PK
- Have urine tests
- Have bone marrow aspirate performed as needed
- Have CT/PET scans (if needed)
- Have Skin lesion assessment/biopsy (if needed)
- Have ECG during screening while on study drug

Study Details

Full Title
A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00092685
NCT: NCT03386513
Phase I
Contact the Duke Recruitment Innovation Center